Product news

Share this article:
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announced that the FDA has approved a supplemental New Drug Application for Nexavar (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma, or liver cancer. Nexavar, an oral anticancer drug, is the first approved systemic therapy for liver cancer and the only one shown to significantly improve overall survival in patients with the disease.
 
Wyeth, announced that the FDA has approved Protonix (pantoprazole sodium) delayed-release oral suspension, providing adult patients who cannot swallow tablets with an effective and convenient way to treat their erosive gastroesophageal reflux disease.
 
AstraZeneca said the FDA has approved once-daily Seroquel XR (quetiapine fumarate) extended-release tablets for maintenance treatment of schizophrenia in adult patients.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.